Pharmacological therapeutics targeting the secondary defects and downstream pathology of Duchenne muscular dystrophy
about
Non-Glycanated Biglycan and LTBP4: Leveraging the extracellular matrix for Duchenne Muscular Dystrophy therapeutics.Myostatin and activin blockade by engineered follistatin results in hypertrophy and improves dystrophic pathology in mdx mouse more than myostatin blockade aloneHuman Galectin-1 Improves Sarcolemma Stability and Muscle Vascularization in the mdx Mouse Model of Duchenne Muscular Dystrophy
P2860
Pharmacological therapeutics targeting the secondary defects and downstream pathology of Duchenne muscular dystrophy
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Pharmacological therapeutics t ...... of Duchenne muscular dystrophy
@en
Pharmacological therapeutics t ...... f Duchenne muscular dystrophy.
@nl
type
label
Pharmacological therapeutics t ...... of Duchenne muscular dystrophy
@en
Pharmacological therapeutics t ...... f Duchenne muscular dystrophy.
@nl
prefLabel
Pharmacological therapeutics t ...... of Duchenne muscular dystrophy
@en
Pharmacological therapeutics t ...... f Duchenne muscular dystrophy.
@nl
P2860
P1476
Pharmacological therapeutics t ...... of Duchenne muscular dystrophy
@en
P2093
Janelle M Spinazzola
Louis M Kunkel
P2860
P304
P356
10.1080/21678707.2016.1240613
P577
2016-10-18T00:00:00Z